Dyne Therapeutics, Inc. (DYN)
After hours:
Dyne Therapeutics, Inc.
1560 Trapelo Road
Waltham, MA 02451
United States
781 786 8230
https://www.dyne-tx.com
Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 141
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Ms. Susanna Gatti High M.B.A. | Chief Operating Officer | 754.1k | N/A | 1968 |
| Dr. Jonathan McNeill M.D. | Chief Business Officer | 662.34k | N/A | 1985 |
| Mr. John G. Cox M.B.A. | CEO, President & Director | N/A | N/A | 1963 |
| Dr. Romesh Subramanian Ph.D. | Co-Founder & Advisor | 565.17k | N/A | 1965 |
| Mr. Richard William Scalzo M.B.A. | Senior VP and Head of Finance & Administration | N/A | N/A | 1986 |
| Mr. John Najim M.B.A. | Chief Technical Officer | N/A | N/A | N/A |
| Dr. Oxana Beskrovnaya Ph.D. | Chief Scientific Officer | 631.08k | N/A | 1961 |
| Ms. Amy Reilly | Senior VP and Head of Corporate Communications & Investor Relations | N/A | N/A | 1974 |
| Mr. Daniel Wilson | Senior VP & Head of Legal | N/A | N/A | 1972 |
| Ms. Kate Mitchell | VP & Head of Human Resources | N/A | N/A | N/A |
Description
Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.
Corporate Governance
Dyne Therapeutics, Inc.’s ISS Governance QualityScore as of April 1, 2024 is 9. The pillar scores are Audit: 7; Board: 7; Shareholder Rights: 8; Compensation: 10.
